First experience with the 2005 modified Gore Helex ASD occluder system
- PMID: 16845573
- DOI: 10.1007/s00392-006-0413-8
First experience with the 2005 modified Gore Helex ASD occluder system
Abstract
We report about our initial experience for the in 2005 modified Helex (Gore) device for closure of atrial septal defects (ASD) and persistent foramen ovale (PFO). Major changes were made at the delivery system for simplifying the Helex implantation procedure. We treated 11 patients, 8 children and 3 adults, with ages between 3 and 62 years. In 10 patients the diagnosis was a relevant ASD with volume overload of the right heart (Left to right shunts between 30 and 50%). One adult (age 58 years) have had a small left to right shunt with a PFO-like defect and the history of 2 neurologic embolic events. In 3 patients we found 2 defects. In all patients a Helex occluder was implanted successfully. The mean fluoroscopy time was 8,4 minutes. The immediate occlusion rate after 24 hours was 91%. In all cases there was a very good adaptation of the device to the anatomical structures. In this small series, the Helex occluder appears to offer a reliable system of occlusion for small and moderate ASDs and for PFO with minimal risk of major complications.
Similar articles
-
Results of the U.S. Food and Drug Administration continued access clinical trial of the GORE HELEX septal occluder for secundum atrial septal defect.JACC Cardiovasc Interv. 2014 Aug;7(8):905-12. doi: 10.1016/j.jcin.2014.01.169. JACC Cardiovasc Interv. 2014. PMID: 25147036 Clinical Trial.
-
Helex septal occluder: feasibility study of closure of atrial septal defect.Pediatr Cardiol. 2008 Jan;29(1):84-9. doi: 10.1007/s00246-007-9053-7. Epub 2007 Sep 25. Pediatr Cardiol. 2008. PMID: 17899244
-
Initial experience in Brazil with the Helex septal occluder for percutaneous occlusion of atrial septal defects.Arq Bras Cardiol. 2003 Nov;81(5):435-52. doi: 10.1590/s0066-782x2003001300001. Epub 2003 Dec 1. Arq Bras Cardiol. 2003. PMID: 14666265 English, Portuguese.
-
Combined prospective United States clinical study data for the GORE(®) HELEX(®) septal occluder device.Catheter Cardiovasc Interv. 2014 May 1;83(6):944-52. doi: 10.1002/ccd.24987. Epub 2014 Jan 31. Catheter Cardiovasc Interv. 2014. PMID: 23674380 Review.
-
Short and long term complications of device closure of atrial septal defect and patent foramen ovale: meta-analysis of 28,142 patients from 203 studies.Catheter Cardiovasc Interv. 2013 Dec 1;82(7):1123-38. doi: 10.1002/ccd.24875. Epub 2013 Aug 31. Catheter Cardiovasc Interv. 2013. PMID: 23412921 Review.
Cited by
-
Platypnoea-orthodeoxia-syndrome in a 69-year-old male: a case report.Clin Res Cardiol. 2008 Jun;97(6):402-6. doi: 10.1007/s00392-008-0640-2. Epub 2008 Feb 22. Clin Res Cardiol. 2008. PMID: 18297325 No abstract available.
-
Transcatheter closure of secundum atrial septal defects in adults with the Amplatzer septal occluder: intermediate and long-term results.Clin Res Cardiol. 2007 Jun;96(6):340-6. doi: 10.1007/s00392-007-0502-3. Epub 2007 Feb 26. Clin Res Cardiol. 2007. PMID: 17323009
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources